117 related articles for article (PubMed ID: 38828252)
1. Managing the Adverse Events Associated with Pembrolizumab and Lenvatinib Therapy in Endometrial Cancer.
Zribi A; Al Riyami K; Al Zahibi HS; Burney IA
Sultan Qaboos Univ Med J; 2024 May; 24(2):293-297. PubMed ID: 38828252
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M
Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review.
Mo DC; Luo PH; Huang SX; Wang HL; Huang JF
Int Immunopharmacol; 2021 Feb; 91():107281. PubMed ID: 33338862
[TBL] [Abstract][Full Text] [Related]
4. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V
Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418
[TBL] [Abstract][Full Text] [Related]
5. Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab.
Makker V; Taylor MH; Oaknin A; Casado Herraez A; Orlowski R; Dutta L; Ren M; Zale M; O'Malley DM
Oncologist; 2021 Sep; 26(9):e1599-e1608. PubMed ID: 34190370
[TBL] [Abstract][Full Text] [Related]
6. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
Makker V; Taylor MH; Aghajanian C; Oaknin A; Mier J; Cohn AL; Romeo M; Bratos R; Brose MS; DiSimone C; Messing M; Stepan DE; Dutcus CE; Wu J; Schmidt EV; Orlowski R; Sachdev P; Shumaker R; Casado Herraez A
J Clin Oncol; 2020 Sep; 38(26):2981-2992. PubMed ID: 32167863
[TBL] [Abstract][Full Text] [Related]
7. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib plus Pembrolizumab Combination Therapy for Advanced or Recurrent Endometrial Cancer: A Single-Center, Retrospective Analysis.
Tochigi M; Shigeta S; Shimada M; Miyahara S; Hasegawa-Minato J; Shibuya Y; Ishibashi M; Hashimoto C; Tokunaga H; Yaegashi N
Tohoku J Exp Med; 2024 Feb; 262(2):85-95. PubMed ID: 38008437
[TBL] [Abstract][Full Text] [Related]
9. A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: insights from ProMisE molecular classification system.
Chiba Y; Kagabu M; Osakabe M; Ito R; Sato S; Takatori E; Kaido Y; Nagasawa T; Shoji T; Yanagawa N; Baba T
Jpn J Clin Oncol; 2024 Apr; 54(4):424-433. PubMed ID: 38251744
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
Makker V; Colombo N; Casado Herráez A; Santin AD; Colomba E; Miller DS; Fujiwara K; Pignata S; Baron-Hay S; Ray-Coquard I; Shapira-Frommer R; Ushijima K; Sakata J; Yonemori K; Kim YM; Guerra EM; Sanli UA; McCormack MM; Smith AD; Keefe S; Bird S; Dutta L; Orlowski RJ; Lorusso D;
N Engl J Med; 2022 Feb; 386(5):437-448. PubMed ID: 35045221
[TBL] [Abstract][Full Text] [Related]
11. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
Taylor MH; Lee CH; Makker V; Rasco D; Dutcus CE; Wu J; Stepan DE; Shumaker RC; Motzer RJ
J Clin Oncol; 2020 Apr; 38(11):1154-1163. PubMed ID: 31961766
[TBL] [Abstract][Full Text] [Related]
12. Gas Bubbles: A Persistent Problem with Immunotherapy.
Yik B; Shah N
Dig Dis Sci; 2021 Aug; 66(8):2542-2544. PubMed ID: 33403485
[No Abstract] [Full Text] [Related]
13. Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.
Yonemori K; Fujiwara K; Hasegawa K; Yunokawa M; Ushijima K; Suzuki S; Shikama A; Minobe S; Usami T; Kim JW; Kim BG; Wang PH; Chang TC; Yamamoto K; Han S; McKenzie J; Orlowski RJ; Miura T; Makker V; Man Kim Y
J Gynecol Oncol; 2024 Mar; 35(2):e40. PubMed ID: 38302725
[TBL] [Abstract][Full Text] [Related]
14. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer.
How JA; Patel S; Fellman B; Lu KH; Hwu P; Ramondetta LM; Westin SN; Fleming ND; Soliman PT; Jazaeri AA
Gynecol Oncol; 2021 Jul; 162(1):24-31. PubMed ID: 33958211
[TBL] [Abstract][Full Text] [Related]
15. Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancer.
Chen TH; Chang PM; Yang MH
J Chin Med Assoc; 2021 Apr; 84(4):361-367. PubMed ID: 33496513
[TBL] [Abstract][Full Text] [Related]
16. Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer.
Zammarrelli WA; Ma W; Espino K; Gordhandas S; Yeoshoua E; Ehmann S; Zhou Q; Iasonos A; Abu-Rustum NR; Aghajanian C; Green AK; Rubinstein MM; Makker V
Gynecol Oncol; 2023 Nov; 178():27-35. PubMed ID: 37748268
[TBL] [Abstract][Full Text] [Related]
17. Real-world utilization of lenvatinib and pembrolizumab combination therapy for the treatment of endometrial cancer in the USA.
Wada K; Zhang J; Lee I; Wang Y; Near A; Prabhu VS
Future Oncol; 2024 Feb; 20(5):257-267. PubMed ID: 37828843
[TBL] [Abstract][Full Text] [Related]
18. [New drug approval: Pembrolizumab plus lenvatinib in second line for patients with advanced or recurrent endometrial cancer].
De Jesus C; Rodrigues M
Bull Cancer; 2022; 109(7-8):740-741. PubMed ID: 35672187
[No Abstract] [Full Text] [Related]
19. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial.
Kawazoe A; Fukuoka S; Nakamura Y; Kuboki Y; Wakabayashi M; Nomura S; Mikamoto Y; Shima H; Fujishiro N; Higuchi T; Sato A; Kuwata T; Shitara K
Lancet Oncol; 2020 Aug; 21(8):1057-1065. PubMed ID: 32589866
[TBL] [Abstract][Full Text] [Related]
20. FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis.
Arora S; Balasubramaniam S; Zhang W; Zhang L; Sridhara R; Spillman D; Mathai JP; Scott B; Golding SJ; Coory M; Pazdur R; Beaver JA
Clin Cancer Res; 2020 Oct; 26(19):5062-5067. PubMed ID: 32295834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]